SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-059093
Filing Date
2024-05-14
Accepted
2024-05-14 07:55:35
Documents
16
Period of Report
2024-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pyxs-20240514.htm   iXBRL 8-K 39764
2 EX-99.1 pyxs-ex99_1.htm EX-99.1 168587
3 GRAPHIC img244827169_0.jpg GRAPHIC 7119
4 GRAPHIC img244827169_1.jpg GRAPHIC 436784
5 GRAPHIC img244827169_2.jpg GRAPHIC 419535
6 GRAPHIC img244827169_3.jpg GRAPHIC 357270
  Complete submission text file 0000950170-24-059093.txt   2022161

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pyxs-20240514.xsd EX-101.SCH 25998
19 EXTRACTED XBRL INSTANCE DOCUMENT pyxs-20240514_htm.xml XML 4911
Mailing Address 321 HARRISON AVENUE BOSTON MA 02118
Business Address 321 HARRISON AVENUE BOSTON MA 02118 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

IRS No.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40881 | Film No.: 24941494
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)